Lanzhou Foci Pharmaceutical Co Ltd Total Liabilities
Lanzhou Foci Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Lanzhou Foci Pharmaceutical Co Ltd (002644) has total liabilities worth CN¥678.01 Million CNY (≈ $99.21 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Lanzhou Foci Pharmaceutical Co Ltd (002644) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lanzhou Foci Pharmaceutical Co Ltd (2007–2024)
Total liabilities of Lanzhou Foci Pharmaceutical Co Ltd from 2007 to 2024. This chart illustrates how Lanzhou Foci Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 002644 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Lanzhou Foci Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Lanzhou Foci Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Consensus Cloud Solutions Inc
NASDAQ:CCSI
|
USA | $650.04 Million |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-C
|
Sweden | Skr3.89 Trillion |
|
MK Restaurant Group Public Company Limited
BK:M
|
Thailand | ฿5.74 Billion |
|
ZJAMP Group Co Ltd
SHE:002758
|
China | CN¥17.15 Billion |
|
Woori Technology Inc
KQ:032820
|
Korea | ₩196.54 Billion |
|
Jilin Liyuan Precision Manufacturing Co Ltd
SHE:002501
|
China | CN¥835.05 Million |
|
Vulcan Steel Ltd
AU:VSL
|
Australia | AU$787.93 Million |
|
Nova Technology
TWO:6613
|
Taiwan | NT$6.96 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Lanzhou Foci Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Lanzhou Foci Pharmaceutical Co Ltd total assets.
Liquidity & Leverage Metrics
Lanzhou Foci Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Lanzhou Foci Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lanzhou Foci Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lanzhou Foci Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual total liabilities of Lanzhou Foci Pharmaceutical Co Ltd from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥654.81 Million ≈ $95.82 Million |
-13.80% |
| 2023-12-31 | CN¥759.67 Million ≈ $111.16 Million |
-10.90% |
| 2022-12-31 | CN¥852.60 Million ≈ $124.76 Million |
+17.67% |
| 2021-12-31 | CN¥724.59 Million ≈ $106.03 Million |
-9.44% |
| 2020-12-31 | CN¥800.08 Million ≈ $117.08 Million |
-10.48% |
| 2019-12-31 | CN¥893.78 Million ≈ $130.79 Million |
-17.52% |
| 2018-12-31 | CN¥1.08 Billion ≈ $158.56 Million |
+9.38% |
| 2017-12-31 | CN¥990.68 Million ≈ $144.97 Million |
+32.78% |
| 2016-12-31 | CN¥746.13 Million ≈ $109.18 Million |
+479.45% |
| 2015-12-31 | CN¥128.77 Million ≈ $18.84 Million |
-58.65% |
| 2014-12-31 | CN¥311.40 Million ≈ $45.57 Million |
+55.93% |
| 2013-12-31 | CN¥199.70 Million ≈ $29.22 Million |
+35.50% |
| 2012-12-31 | CN¥147.38 Million ≈ $21.57 Million |
-18.64% |
| 2011-12-31 | CN¥181.14 Million ≈ $26.51 Million |
+39.67% |
| 2010-12-31 | CN¥129.70 Million ≈ $18.98 Million |
-23.30% |
| 2009-12-31 | CN¥169.09 Million ≈ $24.74 Million |
-7.96% |
| 2008-12-31 | CN¥183.70 Million ≈ $26.88 Million |
+11.53% |
| 2007-12-31 | CN¥164.72 Million ≈ $24.10 Million |
-- |
About Lanzhou Foci Pharmaceutical Co Ltd
LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing … Read more